We’ve brought you some great news from the gadolinium contrast agent litigation last year and the hits just keeping on coming. This time out of federal court in Arizona. And while the court is giving plaintiff another stab at re-pleading her case, we are doubtful plaintiff will be able to cure the deficiencies identified in
Not Your Brother’s Keeper
This post comes from the non-Reed Smith side of the blog.
The phrase may be biblical in origin, coming from the story of Cain and Abel, but its meaning certainly persists and has relevance today. Being both a sibling and a parent of siblings, this blogger doesn’t want to give the impression that her family
A Bit of Patchwork From Pennsylvania
Patchwork is a type of needlework that involves sewing together pieces of fabric into a larger design, usually based on some repeating pattern. The fabric pieces can be different shapes and different colors that are then pieced together. Evidence of patchwork was found in Egyptian tombs. We tend to think of it more in terms
Is This the Final Blow for the Accutane Litigation?
Last year we posted about two major decisions by the New Jersey Supreme Court finally chopping the Accutane inflammatory bowel disease (“IBD”) litigation down to size. Our post here contains links to all of our posts over the years on the Accutane litigation. The point of note is that to get to those two decisions
New Jersey Gives PMA Medical Device Case the Cold Shoulder
t’s cold in New Jersey now. At the time this post hits the blog, it will be about 20 degrees, real feel 15 degrees in most of New Jersey. That’s too cold for this blogger. That’s an extra-large cup of coffee for the ride to work. That’s two-layers of clothing to walk the dog. That’s
Lanham Act Claim Dismissed as Usurping FDA Authority
While the focus of this blog is on product liability cases, we have had occasion to touch upon Lanham Act cases involving litigation between commercial competitors. One reason is because Lanham Act cases provided significant early precedent for the principle that FDA exclusive enforcement powers prohibit plaintiffs from bringing what amount to private FDCA violation
Mensing Applies to Cross-Claims Too
We all know that absent extraordinary circumstances, failure to warn claims against generic drug manufacturers are preempted under PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011). But as far as we are aware, no other court has been asked to decide whether that same preemption applies to cross-claims for contribution or indemnity. Until now.
Malfunction Theory and Medical Malpractice Don’t Mix in Pennsylvania
This post is solely by the non-Reed Smith side of the Blog.
There are lots of great pairings. Bud Abbott and Lou Costello. Paul Simon and Art Garfunkel. Michael Jordan and Scottie Pippen. Michael Scott and Dwight Schrute. Rum and coke. Chocolate and peanut butter. Chocolate and pretzels. Chocolate and strawberries. Chocolate and wine. We
It’s All About Home
It’s pretty easy to find well-known references to home. Home is where the heart is. Home Sweet Home. Homeward Bound. Lassie Come Home. ET phone home. Home is meant to strike up feelings of warmth, safety, happiness. No wonder it’s all over our songs, movies, and television. And, perhaps at no time more so then
Could FDA Warning Letters Be Final Agency Action?
You’ll find any number of places on this blog where we argue emphatically that FDA warning letters are far from final and therefore should not be able to be used in products liability actions. See here for our latest post on the issue (which also collects our other posts). These posts cite case law, FDA